Anti-tumor activity of BH-30643, a novel macrocyclic kinase inhibitor, in EGFR-mutant lung cancer models. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
A recent study comparing young and aged mouse intestinal tissues revealed a delicate balance between IFN-γ signaling and ERK/MAPK signaling as crucial for maintaining the intestinal stem cell ...
Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to ...
CAMBRIDGE, Mass., Feb. 28, 2023 /PRNewswire/ -- Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback